Results 1 to 10 of about 8,117 (271)

Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study [PDF]

Respiratory Research, 2023
Background The efficacy of benralizumab has been broadly demonstrated in severe eosinophilic asthma (SEA), but only few real-life studies evaluated its long-term effects.
Alessandra Vultaggio, Maria Aliani, Elena Altieri, Pietro Bracciale, Luisa Brussino, Maria Filomena Caiaffa, Paolo Cameli, Giorgio Walter Canonica, Cristiano Caruso, Stefano Centanni, Maria D’Amato, Fausto De Michele, Stefano Del Giacco, Fabiano Di Marco, Francesco Menzella, Girolamo Pelaia, Paola Rogliani, Micaela Romagnoli, Pietro Schino, Gianenrico Senna, Marco Benci, Silvia Boarino, Jan Walter Schroeder   +22 more
doaj   +6 more sources

Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis [PDF]

Frontiers in Allergy, 2022
BackgroundSevere eosinophilic asthma (SEA) in the presence of chronic rhinosinusitis with nasal polyps (CRSwNP) indicates the presence of a more extensive eosinophilic inflammation.
Magdi S Mahmoud, Francesco Menzella, Luisa Brussino   +2 more
exaly   +10 more sources

Benralizumab treatment in an elderly patient with eosinophilic esophagitis resulted in remission: a case report [PDF]

BMC Geriatrics
Background Interleukin-5 (IL-5) has recently been shown to play a crucial role in eosinophil-mediated diseases, implying that an IL-5 receptor alpha chain (IL-5Rα) antibody (benralizumab) can be effective against eosinophilic esophagitis (EoE).
Azusa Ishii, Tomofumi Shibata, Yohei Tsunoda, Takafumi Kayukawa, Masahiro Kobayashi, Masami Orinaka, Shoko Miyamatsu, Yoshio Ryuge, Shuichi Asano, Ichidai Tanaka   +9 more
doaj   +3 more sources

Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study [PDF]

Journal of Asthma and Allergy
Purpose: Severe eosinophilic asthma (SEA) patients often present overlapping inflammatory features rendering them eligible for multiple biologic therapies; switching biologic treatment is a strategy adopted to optimize asthma control when patients show ...
Aliani, Maria, Altieri, Elena, Benci, Marco, Boarino, Silvia, Bracciale, Pietro, Brussino, Luisa, Caiaffa, Maria Filomena, Cameli, Paolo, Canonica, Giorgio, Caruso, Cristiano, Centanni, Stefano, D'Amato, Maria, De Michele, Fausto, Del Giacco, Stefano, Di Marco, Fabiano, Menzella, Francesco, Pelaia, Girolamo, Rogliani, Paola, Romagnoli, Micaela, Schino, Pietro, Schroeder, Jan Walter, Senna, Gianenrico, Vultaggio, Alessandra   +22 more
core   +10 more sources

Persistent Eosinophilic Inflammation Is Not a Feature of Type 2 CRS Patients Failing Anti-IL-5R Therapy and Requiring Class Switching to Anti-IL-4/13. [PDF]

Int Forum Allergy Rhinol
Background: Type 2 inflammation dominates eosinophilic chronic rhinosinusitis (eCRS) and adult onset asthma. IL-4, -5, and -13 are prominent disease mediators. Disease control can be achieved with biologic therapies.
Sacks PL, Meerwein CM, Earls P, Thiel C, Choy C, Campbell RG, Sacks R, Kalish L, Harvey RJ.   +8 more
europepmc   +4 more sources

Long-Term Eosinophil Depletion: A Real-World Perspective on the Safety and Durability of Benralizumab Treatment in Severe Eosinophilic Asthma. [PDF]

J Clin Med
: Background/Objectives: Benralizumab is an anti-IL-5 receptor alpha monoclonal antibody that induces the near-complete depletion of eosinophils. This study aimed to evaluate the long-term safety and effectiveness of benralizumab in patients with ...
Menzella F, Marchi M, Caminati M, Romagnoli M, Micheletto C, Bonato M, Idotta G, Nizzetto M, D'Alba G, Cavenaghi M, Bortoli M, Beghè B, Pini L, Benoni R, Casoni G, Muzzolon R, Michieletto L, Bosi A, Mastrototaro A, Diamandi A, Nalin M, Senna G.   +21 more
europepmc   +4 more sources

Real-World Safety and Effectiveness of Benralizumab in Japanese Patients with Severe Asthma: A Multicenter Prospective Observational Study

Journal of Asthma and Allergy
Masao Yamaguchi,1 Yoshihiro Nishimura,2 Yuko Takumi,3 Nobuya Hayashi,4 Kei Sakamoto,3 Yuji Tohda5 1Division of Respiratory Medicine, Third Department of Medicine, Teikyo University Chiba Medical Center, Ichihara, Chiba, Japan; 2Kita-Harima Medical Center,
Yamaguchi M, Nishimura Y, Takumi Y, Hayashi N, Sakamoto K, Tohda Y   +5 more
doaj   +4 more sources

Effects of anti‐IL5 biological treatments on blood IgE levels in severe asthmatic patients: A real‐life multicentre study (BIONIGE) [PDF]

Clinical and Translational Allergy, 2022
Background Mepolizumab and benralizumab are clinically effective biological treatments for severe eosinophilic asthmatic patients by hampering eosinophilic inflammation. The effects of these compound on the immunoglobulin (Ig)E T2 component are virtually
Marco Contoli, Pierachille Santus, Francesco Menzella, Cindy Rocchi, Dejan Radovanovic, Federico Baraldi, Chiara Martelli, Serena Casanova, Carlo Barbetta, Claudio Micheletto, Nicola Scichilone, Bianca Beghè, Elisiana Carpagnano, Alberto Papi   +13 more
doaj   +2 more sources

Benralizumab reduces blood basophil percentage and activation in vitro without eliciting degranulation [PDF]

Allergy. European Journal of Allergy and Clinical Immunology
PI21 ...
Bernaola, J., Betancor, D., Cañas, Jose Antonio, Fernández-Nieto, Mar, García de Castro, Zahara, Gil Martinez, Marta, Lorente Sorolla, C., Minguez, Pablo, Pinillos-Robles, Erwin J., Pozo Abejón, María Victoria del, Rodrigo Muñoz, Jose M., Rodríguez Nieto, María Jesús, Sastre Domínguez, Joaquín, Valverde-Monge, Marcela   +13 more
core   +4 more sources

Simultaneous treatment with benralizumab and ustekinumab in a patient with severe asthma and ulcerative colitis. [PDF]

Lung India
The burden of autoimmune diseases is rising worldwide. The expansion of the population of patients eligible for severe asthma biological therapy we are seeing in clinical practice could lead to the simultaneous use of different monoclonal antibodies.
Carriera L, Barone R, Ielo S, Coppola A.
europepmc   +3 more sources